ProPhase Labs will present at the ThinkEquity Conference on October 30, 2025, highlighting innovations and investment opportunities.
Quiver AI Summary
ProPhase Labs, Inc. announced its participation in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York, where CEO and Chairman Ted Karkus will present at 11 AM ET. The conference aims to connect institutional investors and industry professionals while showcasing innovative financial strategies. Additionally, one-on-one investor meetings will be available throughout the day, with a live stream of Karkus's presentation accessible online. ProPhase Labs is focused on advancing healthcare through innovative genomic and diagnostic solutions, including a potential early detection test for esophageal cancer and an extensive range of OTC dietary supplements. The company emphasizes its commitment to creating a healthier world and enhancing long-term value through its diverse health and wellness offerings.
Potential Positives
- ProPhase Labs is participating in a prestigious conference, which may increase visibility and attract interest from institutional investors.
- CEO Ted Karkus is presenting at the conference, which could enhance the credibility and profile of the company.
- The company's focus on groundbreaking innovations, such as Whole Genome Sequencing and diagnostics for early cancer detection, positions it favorably in the biotech and consumer products markets.
- The press release highlights a commitment to executional excellence and smart diversification, suggesting a strategic approach to growth and long-term value creation.
Potential Negatives
- None
FAQ
What is the ThinkEquity Conference?
The ThinkEquity Conference gathers institutional investors and industry professionals to discuss innovations and financial strategies.
When will ProPhase Labs present at the conference?
ProPhase Labs will present at 11 AM ET on October 30, 2025.
How can investors participate in one-on-one meetings?
Interested investors can register and schedule one-on-one meetings on the conference website.
Is the ProPhase presentation available for live streaming?
Yes, the presentation will be live-streamed; a link is provided in the press release.
What areas does ProPhase Labs focus on?
ProPhase Labs specializes in biotech, genomics, and consumer products, focusing on health and wellness solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRPH Hedge Fund Activity
We have seen 18 institutional investors add shares of $PRPH stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WEXFORD CAPITAL LP removed 1,525,611 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $596,971
- SYKON CAPITAL LLC added 644,795 shares (+inf%) to their portfolio in Q2 2025, for an estimated $252,308
- FOURWORLD CAPITAL MANAGEMENT LLC removed 376,577 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $147,354
- CITIZENS FINANCIAL GROUP INC/RI removed 270,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $105,807
- JOSH ARNOLD INVESTMENT CONSULTANT, LLC removed 250,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $97,825
- SHEETS SMITH WEALTH MANAGEMENT removed 208,300 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $81,507
- APOLLON WEALTH MANAGEMENT, LLC added 182,464 shares (+inf%) to their portfolio in Q3 2025, for an estimated $83,532
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies.
Ted Karkus, CEO and Chairman of the Board of Directors, will be presenting at 11AM ET on October 30 th . One-on-one investor meetings will be held throughout the day. Interested investors can register to attend and schedule one-on-one meetings here: https://www.meetmax.com/sched/event_121867/conference_home.html
The presentation will also be live-streamed at the following link:
https://event.summitcast.com/view/NX3WagbdCmRzBGMxdc3ia6/guest_book?session_id=PDgxE2V2WRZcL6RynfToZv
About ProPhase Labs Inc.
ProPhase Labs Inc. (Nasdaq: PRPH) (“ProPhase”) is a next-generation biotech, genomics and consumer products company. Our mission is to build a healthier world through bold innovation and actionable insight. We’re revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, groundbreaking diagnostic development, such as our potentially life-saving test for the early detection of esophageal cancer, and a world class direct-to-consumer marketing platform for cutting edge OTC dietary supplements. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs’ valuable subsidiaries, their synergies, and significant growth underscore our potential for long-term value. www.ProPhaseLabs.com
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
[email protected]
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman:
[email protected]
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
